Gossamer Bio Inc. (NASDAQ:GOSS) is a biopharmaceutical company focused on developing treatments for pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company is collaborating with the Chiesi Group to develop seralutinib, a drug aimed at treating PAH. Gossamer Bio's recent activities have significantly impacted its stock performance.
On February 23, 2026, Leerink Partners set a price target of $1 for Gossamer Bio, while the stock was trading at approximately $0.42. This target suggests a potential increase of about 63.76%. However, Leerink also downgraded Gossamer Bio to Market Perform from Outperform, as highlighted by TheFly. This downgrade reflects concerns about the company's recent trial results and their impact on the stock.
Gossamer Bio's stock experienced a decline following the release of topline results from its Phase 3 PROSERA study. This study evaluated seralutinib's efficacy in treating PAH. Although the study narrowly missed a key statistical threshold, it showed potential efficacy, with a median improvement of 28.2 meters in the Six-Minute Walk Distance (6MWD) for patients treated with seralutinib, compared to 13.5 meters in the placebo group.
Despite the study's failure to meet its primary objective, Gossamer Bio plans to engage with the FDA to review the findings. The company aims to present data showing increased activity in patients with advanced stages of PAH. The estimated treatment effect was 13.3 meters, with a p-value of 0.0320, indicating potential efficacy despite not meeting the prespecified threshold.
Gossamer Bio's stock is currently priced at $0.42, reflecting a significant decrease of 80.13% in its value. The stock has fluctuated between a low of $0.33 and a high of $0.60 today. Over the past year, it reached a high of $3.87 and a low of $0.33. The company's market capitalization is approximately $97.98 million, with a trading volume of 271.71 million shares on the NASDAQ exchange.
